Target intelligence / Profile preview

Egl nine homolog 1 (EGLN1)

Target
EGLN1
Molecular classification
Enzyme, Dioxygenase, Prolyl hydroxylase
01

Overview

Egl nine homolog 1 (EGLN1), also widely known as prolyl hydroxylase domain-containing protein 2 (PHD2), is a non-heme iron-containing dioxygenase that serves as the primary cellular oxygen sensor in humans. Under normoxic conditions, EGLN1/PHD2 utilizes oxygen and 2-oxoglutarate as co-substrates to hydroxylate specific proline residues on the alpha subunits of hypoxia-inducible factors (HIF-1α and HIF-2α). This post-translational modification targets HIF-α for ubiquitination by the von Hippel-Lindau (VHL) E3 ligase complex and subsequent proteasomal degradation. In hypoxia, the enzyme's activity is suppressed, allowing HIF-α to accumulate, translocate to the nucleus, and activate transcription of genes regulating erythropoiesis, angiogenesis, and anaerobic metabolism. Small-molecule inhibitors of EGLN1/PHD2, such as roxadustat, daprodustat, and vadadustat, mimic hypoxia by competitively binding to the enzyme's active site. This stabilization of HIF-α stimulates endogenous erythropoietin (EPO) production and improves iron mobilization, making EGLN1/PHD2 a major therapeutic target for anemia associated with chronic kidney disease (CKD).

Other names
Prolyl hydroxylase domain-containing protein 2PHD2Hypoxia-inducible factor prolyl hydroxylase 2HIF-PH2Egl-9 family hypoxia-inducible factor 1Egl nine-like protein 1Zinc finger MYND domain-containing protein 6
02

Mechanism of action

EGLN1/PHD2 inhibitors act as 2-oxoglutarate (2-OG) mimetics and/or iron chelators that bind to the active site of the enzyme. This competitive inhibition prevents the hydroxylation of proline residues on HIF-1α and HIF-2α, thereby blocking their recognition by the von Hippel-Lindau (VHL) tumor suppressor and subsequent proteasomal degradation. The resulting stabilization and nuclear translocation of HIF-α subunits lead to the transcriptional activation of target genes, most notably erythropoietin (EPO), which stimulates red blood cell production.

03

Biological functions

Oxygen sensingProtein hydroxylationProteasomal degradation regulationRegulation of transcriptionErythropoiesisAngiogenesisMetabolic reprogramming
04

Disease associations

AnemiaChronic kidney diseaseIschemiaCardiovascular diseaseCancerErythrocytosis
05

Safety considerations

Cardiovascular eventsThrombosisHypertensionSepsis and severe infectionsPotential tumor progression or angiogenesis promotion
06

Interacting drugs

5 more in the full profile.

07

Biomarkers

HemoglobinHematocritErythropoietin (EPO)HIF-1alphaHIF-2alphaHepcidin

Beyond the preview

Go deeper on Egl nine homolog 1 (EGLN1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Egl nine homolog 1 (EGLN1).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call